Daniel Meier

Daniel Meier

Director Europe

Tel. +41 61 295 50 04

report Life Sciences



SpiroChem building on successful year

SpiroChem, a Swiss fine chemicals company based in Basel, achieved significant growth in revenue and number of customers last year. This course is to be maintained in 2018.

The last year was characterised by important changes for SpiroChem. The spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) relocated from Zurich to state-of-the-art facilities in the Rosental area of Basel. It also successfully concluded a financing round. In a press release, the company reported that revenue growth was over 40 per cent, while the number of new customers increased by 36 per cent in comparison with the previous year.

SpiroChem produces new classes of molecules that are used in the R&D of medications. It offers innovative solutions for the pharmaceuticals industry. To achieve the company vision of being the leading chemical innovation provider, SpiroChem works in partnership with its customers.  This has resulted in a pipeline of new products, which will be launched in the near future.

In 2018, SpiroChem intends to maintain its successful course and focus on organic growth, while at the same time targeting larger deals with customers. The Basel-based company thus hopes to reinforce and build on its reputation as the partner of choice for the implementation of complex chemistry projects.

Cookies uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.